Consumer Alert: FOSAMAX® Litigation Claiming Jaw Death and Femur Fractures

Copyright 2012.  All rights reserved.

FOSAMAX®, used for the prevention and treatment of osteopenia and osteoporosis, has caused many people to suffer painful osteonecrosis (bone death) of the jaw and atypical femur fractures since its introduction in 1995.[1] These femur fractures often require surgery and involve a long recovery and rehabilitation process. Our attorneys are actively litigating cases in the FOSAMAX® jaw injury MDL in New York and in the recently-established FOSAMAX® femur fracture MDL in New Jersey.

[1] See ODS Postmarketing Safety Review, Department of Health and Human Services, Public Health Service, U.S. Food and Drug Administration, Aug. 25, 2004 and U.S. Food and Drug Administration, Safety Announcement, Additional Information for Patients, Additional Information for Healthcare Professionals, Data Summary (October 2010), both available at www.fda.gov.

The articles on our Web site include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice or as an expression of the views of the firm, its attorneys or any of its clients. We hope the articles spur discussion in the legal community with insight into the experience of the authors. We expressly reserve the right in the future to become wiser or simply change our mind.